Sage Journals: Discover world-class research

Abstract

Male breast cancer (MBC), one of the rare types of cancer among men where the global incidence rate is 1.8% of all breast cancers cases with a yearly increase in a pace of 1.1%. Since the last 10 years, the incidence has been increased from 7.2% to 10.3% and the mortality rate was decreased from 11% to 3.8%. Nevertheless, the rate of diagnoses has been expected to be around 2.6% in the near future, still there is a great lack in studies to characterize the MBC including the developed countries. Based on our search, it is evidenced from the literature that the number of risk factors for the cause of MBC are significant, which includes the increase in age, family genetic history, mutations in specific genes due to various environmental impacts, hormonal imbalance and unregulated expression receptors for specific hormones of high levels of estrogen or androgen receptors compared to females. MBCs are broadly classified into ductal and lobular carcinomas with further sub-types, with some of the symptoms including a lump or swelling in the breast, redness of flaky skin in the breast, irritation and nipple discharge that is similar to the female breast cancer (FBC). The most common diagnostic tools currently in use are the ultrasound guided sonography, mammography, and biopsies. Treatment modalities for MBC include surgery, radiotherapy, chemotherapy, hormonal therapy, and targeted therapies. However, the guidelines followed for the diagnosis and treatment modalities of MBC are mostly based on FBC that is due to the lack of prospective studies related to MBC. However, there are distinct clinical and molecular features of MBC, it is a need to develop different clinical methods with more multinational approaches to help oncologist to improve care for MBC patients.

Keywords

male breast cancer epidemiology risk factors diagnosis of MBC treatment modalities

Introduction

Globally cancer is one of the leading non-communicable diseases and is responsible for a majority of death in both males and females. Therefore, it is considered as main barriers in increasing life expectancy and decreasing mortality worldwide.^1,2 One of the globally identified most burdensome is the breast cancer (BC) and responsible for higher incidence of death in females.³ Even though BC in male is rare/uncommon type of cancers, the global incidence rate is reported as 1.8% of all BC cases⁴ with a yearly increase in a pace of 1.1%^4‐8 where the incidence in Indian population is also similar to the global rate.^9,10 Till the hormones influence the differentiation during the puberty, breast tissues in both male and female are identical.¹¹ Boys during their pubertal age will have increased level of estrogen along with a 30-fold increase in testosterone levels. Estrogen stimulation of the growth of breast tissue will normally be antagonized by the androgen in males. Hence, male breast is normally characterized as fat mass in sub-cutaneous area along with residue in sub-areolar tissues of the ductal region.¹²

BC in men is one of the rare/uncommon forms of malignancy and is not fully understood. A unimodal peak at the age of 71 years reported in male based on age distribution in men with BC might be delayed diagnosis due to low suspicion⁷ whereas, in women a bimodal distribution with peaks at 52 and 71 years of age were identified.¹³ Identified risk factors for most of the BC cases in both sexes are unknown. Though comparative studies on the risk factors of BC in women and men are inadequate, certain factors like BRCA2 mutations had been ascertained to be a common risk factor for both sexes.

Male breast cancer (MBC) accounts for a small fraction of all BC cases and presents unique challenges in terms of prevention, early detection, and management. One of the key aspects in preventing MBC involves understanding the risk factors associated with its development. One of the major risk factors concerning MBC is the genetic predisposition, and is reported that inherited germline variants in BRCA1 and BRCA2 account for approximately 2% and 10% of MBC respectively with a life time risk in men harboring BRCA1 and BRCA2 mutations is 1.2% and 6.8%.¹⁴ In light of this, genetic counseling and testing are strongly recommended for individuals with a family history of breast and ovarian cancers.¹⁵ Cautious use or avoidance of estrogen-containing hormone replacement therapy is advisable for men with a history of conditions such as gynecomastia or other breast-related issues, as this can help in reducing the risk of MBC.¹⁶ Moreover, promoting lifestyle modifications is crucial in MBC prevention. Encouraging men to maintain a healthy body weight, engage in regular physical activity, and limited alcohol consumption not only contributes to their overall well-being but also plays a role in lowering the risk of BC, mirroring the benefits observed in women's BC prevention strategies.

Early detection and screening are vital components in the management of MBC. It is imperative to educate men about the importance of self-awareness when it comes to their breast health. This includes encouraging them to perform regular breast self-examinations and promptly reporting any unusual findings to a healthcare provider. Additionally, routine clinical breast examinations by healthcare professionals play a crucial role in detecting MBC, particularly among individuals at higher risk. Even though mammography is considered to be a common screening tool for BC, it is reported that mammography in men is highly sensitive and specific, which might lead to high negative predictive value.^17,18 Bearing in mind the limitations of using mammography to diagnose MBC, it is worthwhile to consider using appropriate diagnostic tool such as genetic counselling for men those with elevated risk factors, including family history of BC or known genetic mutations¹⁹ for early detection and to increase the chances of treatment success.

The primary approach in managing MBC involves surgery encompassing mastectomy, which involves the complete removal of the breast, or breast-conserving surgery, depending on the need. Additionally, the management of MBC may entail to adjuvant therapies, which includes chemotherapy, radiation therapy, and hormone therapy, with the focus of reducing the risk of recurrence. The post-treatment phase of MBC is marked by a focus on follow-up and survivorship care. Regular follow-up examinations are essential to monitor for any signs of recurrence or potential complications arising from the treatment received. Additionally, emphasizing lifestyle management is vital in enhancing the overall well-being of MBC survivors. Furthermore, participation in cancer support groups or survivorship programs can offer MBC survivors an invaluable source of emotional support and a sense of community. These support networks provide a safe space for individuals to share experiences, exchange advice, and navigate the unique challenges that come with surviving MBC, fostering resilience and improving the quality of life for those on to the survivorship journey.

Epidemiology

The incidence of MBC will greatly differ with geographic areas and race.^14,20 It is reported that in comparison to the Asian Countries, the frequency of MBC is much higher in the North America and Europe.²¹ The epidemiology of MBC has changed significantly over the last 10 years. The American Cancer Society (ACS) reported that the estimated new cases of MBC in the year 2019 as 2670 with 18% mortality rate.¹³ Subsequently it has been reported that rate of MBC diagnoses was expected to be around 2.6% in the year 2023 of all newly diagnosed cases with an estimation of 3200 men would be diagnosed and reported that the occurrence of MBC has been raised from 7.2% to 10.3% over the last 10 years and the mortality rate was decreased from 11% to 3.8%.²² The incidence and 5-year survival rate of MBC in the last 20 years is depicted in Figure 1.

Figure 1.

Incidence and 5-year survival rate of MBC in the last 20 years.

According to the SEER data, a significant raise in the rate of MBC, which exceeds at least 25% higher than that of women has been reported.²³ The ACS has predicted almost 2800 new cases in the United States with 530 deaths by the end of the year 2023.²⁴

Etiology

In spite of the increase in the global rate of MBC in the last 3 decades,²⁵ studies showing the etiology, prognosis, and treatment is seldom available, as most of the population-based studies and clinical trials focused on MBC is very limited.²⁶ However, guidelines for the treatment and clinical management for managing MBC are being used those which have been developed and followed based on female BC. The risk of BC in men increases with increasing age of an average between 60 and 70 years, with most cases happening in men over the age of 50 years old.^22,27,28 The 5-year survival rate for MBC in India is estimated to be around 56%.^29‐32 Even though there are no solid evidences stating the mechanism of MBC, some reports have reported that MBC are more likely to express high levels of either estrogen receptors (ERs) or androgen receptors compared to female with a minimal or no expression of HER2.^7,23,33

Identified risk factors for the cause of MBC are familial history, radiation exposure of the chest in the past, engorged breasts, exposure to estrogen, overweight, inherited gene mutation (BRCA1 and BRCA2), and certain medical conditions, including cirrhosis, obesity, Klinefelter syndrome, and so on, may increase the risk. Moreover, certain lifestyle behaviors, such as smoking, over consumption of alcohol, and less or no physical activities could also increase the chances of developing MBC. Men diagnosed with BC typically present with a lump in the breast or nipple discharge and may also include rash, itching, or pain in the breast area.^29,34

Risk Factors

As like female BC, factors including genetic, endocrine compounds, and other environmental risk factors are considered as the major risk factors that can cause MBC. The known risk factors for the cause of MBC are given in Figure 2. A recent review by Fentiman has reported that BRCA2 mutation carriers and individuals with Klinefelter's syndrome are the 2 significant cohorts responsible for up to 15% of MBC cases.³⁵ Moreover, the risk of BC increases at least 2-fold in case of family history and it can be considered as the main predisposing factor.¹⁰ Considering the epidemiological prospective, BC in men most closely resembles the BC in post-menopausal women but the clinical and pathological characteristics are different from each other. Additionally, BC in men has poor prognosis in comparison with female breast cancer (FBC) because of the symptoms appear in unconventional stage in men,^36‐39 where the scenario remains to be the same even decades. Hence, the increase in age is directly proportional to the risk of BC.

Figure 2.

Risk factors of MBC.

Role of Lifestyle Factors, Diet, and Exercise

Several studies have highlighted the role of lifestyle and environmental elements in influencing the onset and advancement of the disease.^40‐44 Among the risk factors, obesity through the hormonal mechanisms emerge as particularly noteworthy due to their potential causal connection with BC and the feasibility of modification.^35,43 Further the studies have also stated that dietary factors, physical activities, and socio-economic status could also deserve for the cause of MBC.^35,43 It is advised to limit saturated fats derived from red and processed meats, full-fat dairy products, and fried foods, as their high consumption is associated with an elevated risk of BC.⁴⁵ Furthermore, added sugars and processed foods, which are crucial to contribute towards weight gain and inflammation, are recognized risk factors for BC.⁴⁶ Additionally, excessive intake of alcohol is also linked to increased risk of BC.⁴⁷

Several studies have reported that eating more dietary fiber from various sources including whole grains, pulses, vegetables, and fruits can supply essential nutrients and antioxidants that bolster overall health and not only reduce the risk of BC in men but also improve the overall survival (OS) rate.^48‐51 Incorporation of a diverse array of colors with a wide spectrum of essential nutrients could ensure prevention of BC.⁵² Lean proteins sourced from poultry, fish, beans, lentils, and tofu provide essential amino acids necessary for cellular repair and maintenance.⁵³ Healthy fats, consumed from avocados, nuts, seeds, and olive oil, support overall well-being and help in reducing inflammation.⁵⁴ Omega-3 fatty acids, found in fatty fish like salmon, mackerel, and chia seeds, possess anti-inflammatory properties that may confer protection against BC.⁵⁵ Antioxidant-rich foods like berries, nuts, and dark leafy greens play a crucial role in neutralizing harmful free radicals in the body.⁵⁶

Green tea, containing compounds such as catechins, has been studied for its potential protective effects against BC.⁵⁷ Turmeric and curcumin, known for their anti-inflammatory and antioxidant properties, may also offer some protective benefits.⁵⁸ It is reported that compared to the omega-6 arachidonic acid, marine omega-3 fatty acids such as eicosapentaenoic acid and docosahexaenoic acid have demonstrated a lower associated risk of BC. Regular exercise is also crucial in this context.⁵⁹

Recent study has demonstrated the significance of heightened lipogenesis in facilitating the self-renewal and proliferation of BC stem cells.⁶⁰ Furthermore, it highlighted the efficacy of omega-3 fatty acids through targeting the site-specific pathways to exert their anticancer properties.⁶⁰ It is also reported that the combination of hydroxytyrosol, omega-3 fatty acids, and curcumin effectively alleviated inflammation, which is evidenced by a decrease in CRP levels, and furthermore the reduction in pain among patients experiencing aromatase-induced musculoskeletal symptoms.⁶¹ Flaxseeds, abundant in fiber, are recommended for improving constipation as they aid in enhancing intestinal function, additionally, they contain omega-3 fatty acids. It is also reported that flaxseed either enhanced or sustained tamoxifen's effectiveness in reducing tumor growth through inhibiting cell proliferation and promoting apoptosis.⁶²

However, several studies have reported due to the germline mutations in the onco-suppressor genes such as BRCA2, p53, ATM, CHEK2, and PALB2, almost around 10% of the cases are hereditary in nature. More specifically it has been reported that mutation in PALB2 gene has at least 8-fold increased risk of developing MBC.^63‐67 As reported above, Kaur et al, in the year 2019 revealed 13 novel missense mutations in 8 genes in MBC patients from Malwa region of Panjab, India.⁶⁸ Genetic profiling of men could be helpful via identification of genetic markers; those which are associated with MBC patients can be helpful in paving way for newer therapeutic strategies and furthermore to design site-specific agents.^69,70 Table 1 shows the various genes and proteins that are more prone for mutation and their functions in MBC.

Table 1.

Genes and Proteins That are More Prone for Mutation and Their Functions in Male Breast Cancer.

S. No.	Gene and protein	Functions	Amino acids involved in the mutation	References
1	BRCA2 (Breast Cancer 2, early onset)	DNA repair mechanism and helps to maintain the genomic stability. Changes in the base pairs called mutation of BRCA2 gene could increase the risk of MBC.	R28C, T397X, N372X	⁷¹
2	BRCA1 (Breast Cancer 1, early onset)	DNA repair and tumor suppressor functions. Although more commonly associated with female breast cancer, mutations in the BRCA1 gene can also increase the risk of male breast cancer.	E198X, R94W, R50X	⁷²
3	PALB2 (Partner and Localizer of BRCA2)	PALB2 interacts with BRCA2 and helps in DNA repair. Mutations in PALB2 have been found to increase at least 2 to 4 times more likely to develop breast cancer on men.		⁷³
4	CHEK2 (Checkpoint Kinase 2)	CHEK2 is involved in cell cycle regulation and DNA repair. Any changes in the base pairs of CHECK2 gene are highly associated with increased risk different cancers including MBC.	del5395insC, 1100delC, IVS2 + 1G > A	⁷⁴
5	PTEN (Phosphatase and Tensin Homolog)	PTEN, a tumor suppressor gene, helps in regulating cell growth and cell division mechanisms. Mutations in PTEN have been linked to various cancers, including male breast cancer.	R130Q, P123Q, E285K	⁷⁵
6	TP53 (Tumor Protein p53)	TP53, a tumor suppressor gene, prevents the development of cancer. Mutations in TP53 have been associated with an increased risk of several cancers, including male breast cancer.	R273H, R282 W, P72R	^76,77
7	RAD51C (RAD51 Homolog C)	RAD51C involved in DNA repair by homologous recombination and its’ mutation is oriented with an increased risk of MBC.	E133K, M117I, A121T	⁷⁸
8	RAD51D (RAD51 Homolog D)	Similar to RAD51C, RAD51D is also involved in DNA repair by homologous recombination and its mutation is oriented with an increased risk of MBC.	V93M, R127X, L182F	⁷⁹
9	NBN (Nibrin)	DNA repair and genomic stability. Mutations in the NBN gene, which codes for the protein nibrin, is associated with increased risk of MBC.	R434X, Q38X, R51C	⁷¹
10	ATM (Ataxia Telangiectasia Mutated)	DNA repair and conservation of genomic stability. Mutation in ATM is associated with an increased risk of MBC.	L2536P, K2518N, A3012T	⁸⁰
11	STK11 (Serine/Threonine Kinase 11)	Cell cycle regulation and tumor suppression. Mutations in STK11 gene have been linked to an increased risk of various cancers, including MBC.	M419K, I323 T, R189X	⁸¹
12	CDH1 (Cadherin 1)	CDH1 codes for the protein E-cadherin, that involve in cell adhesion. Mutation in the CDH1 is associated with an increased risk of various cancers, including MBC.	R168G, P50L, R87Q	⁸²
13	MRE11A (MRE11 Homolog A)	DNA repair and conservation of genomic stability. Mutations in MRE11A have been linked to an increased risk of MBC.	IVS10- 1G > A, R20 W, Y127C	⁸³
14	MLH1 (MutL Homolog 1)	MSH1 involve in DNA mismatch repair, which is essential for maintaining genomic stability. Mutation in MLH1 is associated with an increased risk of MBC.	V741fs, Y179F2, V577G	⁸⁴
15	MSH2 (MutS Homolog 2)	MSH2 are involved in DNA mismatch repair, which is essential for maintaining genomic stability. Mutation in MSH2 is associated with an increased risk of MBC.	D242N, K923E, L420X	⁷⁸
16	MSH6 (MutS Homolog 6)	MSH6 are involved in DNA mismatch repair, which is essential for maintaining genomic stability. Mutation in MSH6 is linked with an increased risk of MBC.	IVS7 + 1G > A, Y978C, Q721H	⁷⁸
17	PPM1D (Protein Phosphatase, Mg²⁺/Mn²⁺ Dependent 1D)	DNA damage response and cell cycle regulation. Mutations in PPM1D have been found to increase the risk of MBC.	P56T, Q71R, R475H	⁸⁵
18	RAD51 (RAD51 Recombinase)	Involve in DNA repair and maintenance of genomic stability. Mutations in RAD50 have been associated with an increased risk of MBC.	F51L, M16T, R59C	⁸⁶
19	RAD50 (RAD50 Double Strand Break Repair Protein)	Involved in DNA repair by homologous recombination. Mutations in these genes have been associated with an increased risk of MBC.	D509N, L206P, R161C	⁸⁷
20	BARD1 (BRCA1 Associated RING Domain 1)	Interacts with BRCA1 and plays a role in DNA repair and tumor suppression. Mutations in BARD1 have been linked to an increased risk MBC.	G33R, Y56H, Q3Q	⁸⁸

The other risk factors include, exposure to estrogen as hormone therapy for prostate cancer; Klinefelter's syndrome, a genetic syndrome, which causes abnormal development of the testicles that produce lower levels of certain male hormones such as androgens and more levels of estrogen, a female hormone. Inflamed testicles (Orchitis) or removal of testicles (Orchiectomy) might also increase the risk of MBC. Certain medical conditions such as hormonal imbalance due to any liver diseases and obesity could also increase the risk of MBC.^89,90 In addition to the above-mentioned risk factors, quite a few more that are related to occupational hazards such as hot working environments, working with chemical and hormonal synthetics, long-term exposure of ionizing radiations and electro-magnetic radiation and chemicals and its’ combustion products are also reported to increase the risk of developing MBC.^91‐93

Types

There are several types and subtypes of MBC classified based on various factors including histology, hormone receptor status, and genetic mutations. Various types of MBC and its characteristics are summarized in Table 2.

Table 2.

Various Types of Breast Cancer in Male and its Characteristics.

Type	Characteristics
Invasive ductal carcinoma (IDC)	One of the most common type in both men and women that start to grow from the milk ducts and invades to nearby tissues of the breast.
Invasive lobular carcinoma (ILB)	Begins in the milk-producing glands called as lobules and can spread to various other parts of the body.
Mixed types	Breast cancer having both the IDC and ILC like characteristics, which are classified as mixed type
Inflammatory breast cancer (IBC)	A rare and aggressive type, without any normal symptoms of any other BC, instead the breast may appear red, swollen and feel warm.
Paget's disease of the nipple	Another rare type of BC that starts in the ducts of the nipple and further spreads to the surface of the nipple and may be associated with any other underlying BC.
Angiosarcoma	This is also a rare type of BC that starts in cells lining blood vessels or lymph vessels in the breast
Phyllodes tumor	This is a rare type of tumor that forms in the connective tissue of the breast. It can be benign (non-cancerous), borderline (potentially cancerous), or malignant (cancerous
Based on hormone and receptor status	Male breast cancers, like female breast cancers, can be classified based on hormone receptor status. This includesEstrogen PositiveProgesterone PositiveHuman Epidermal Growth Factor Receptor Positive
BRCA mutation	Mutations in the BRCA1 and BRCA2 genes, which are known to increase the risk of breast in men and women and ovarian cancers.
Triple-negative breast cancer (TNBC)	Lack or absence of hormone receptors (ER, PR) and does not express HER2, which is one of the most aggressive types.

Ductal Carcinoma In Situ (DCIS)

DCIS in the breast is identified by a lesion confined within the breast ducts, devoid of invasive traits or metastatic potential. Pure DCIS comprises approximately 10% of all MBCs and constitutes less than 0.1% of all cancer types in men. Ensuring a prompt diagnosis of male carcinoma in situ and implementing effective clinical interventions are pivotal in averting its advancement into a more severe form, like invasive carcinoma.⁹⁴ It constitutes roughly 1% of all malignancies in men and accounts for 5% to 7% of MBC cases.⁹⁵

However, studies have reported that as like in women, majority of men have invasive ductal caricnomas,^96‐98 which constitutes about 90% of all MBCs.⁹⁹ However, medullary, papilloma, and lobular are also implicated to be the other types. In spite of the low level of knowledge and awareness and stigmas towards MBC, in-situ ductal carcinoma is found desperately, which leads to delayed diagnosis and poorer patient outcomes. Approximately 90% of MBC expresses ER, and 81% expresses progesterone receptor (PR).^100‐102 Comparatively papillary carcinoma is one of the most prevalent types and lobular carcinomas are rare.¹⁰³ However, a recent study by Chhabra et al, in the year 2021, showed around 81% of ER, 76% PR, 25% HER2neu, and 2% of TNBC in Indian population.²⁹ It is also reported that hormone receptor expression is more common in MBC when compared with FBC.⁹² Hence, inhibition of these receptors could be usually predicted for the treatment and management of MBC, which will be discussed under the treatment modalities in the further sections.

Signs and Symptoms

MBC also shows some of the most common symptoms of FBC such as painless subareolar lump in the breast, nipple retraction called as flattening, nipple inversion where the nipple seems growing inward, fluid discharge from the nipple, redness or scaling of the nipple or breast skin.^104‐106 It is also evidenced that there would be a single preponderance of left-sided versus right-sided disease similar to women.¹⁰⁶ Deficiency of established screening guidelines for MBC is directly reflecting on the delayed diagnosis of the disease. International Male Breast Cancer Program has reported that approximately 46.7% of men with this disease are reported to have at least one lymphnode at the time of diagnosis.³³ Chances of treatment success could be increased with early detection of the disease.

Secondary Malignancies due to BC

Development of the secondary malignancies due to MBC has increased risk of generalized malignancy in a secondary spot. A retrospective registry-based cohort study conducted at the UC Irvine by involving data from the year 1988 to 2023 with 1926 men aged 85 years or less diagnosed with primary BC. Out of the 1926 patients, 221 (11.5%) patients have developed a secondary cancer.¹⁰⁷ The development of second cancer is reported to be more particularly of a 2nd primary cancer of the breast, cutaneous melanoma, and stomach cancer compared with general population. However, younger men are more prone or at high risk of developing second malignancies. An earlier study had reported that 17% of MBC patients have developed prostate cancer out of the total 69 MBC cases identified.^107,108 This might be due to the use of aromatase inhibitor (AI) to treat MBC, which could increase the serum testosterone levels and could enable the growth and proliferation of prostate cancer clones.¹⁰⁹ It is also reported that the other frequent secondary spot for the development of cancer in MBC patients are leukemia, pancreas, small intestine, and rectum.^104,110

Diagnosis

Studies have reported that lack of knowledge and awareness of the disease and delay in diagnosis are the major reasons that usually BC in men are diagnosed at later stages that would pave way for the overall poorer prognosis.^111,112 Recommendation from the American College of Radiology strongly suggests the bilateral ultrasound evaluation for younger aged men (<25 years) with palpable mass, whereas bilateral mammography for men older than 25 years of old.¹¹³ On identification of any lumps or suspicious area in the breast, complete family history with physical examination may lead for distinguishing the BC and to choose the better choice of diagnosis and treatment modalities. Evidences of lumps or suspicious areas with any further possible spread especially the enlarged lymph nodes under the arm by felling the texture, size, and its relationship to the skin and muscle could be diagnosed by complete breast physical examination. Irregular, hypoechoic retro-areolar masses with variable vascularity are some of the most common finding on the ultrasound evaluation whereas similar speculated and radio-dense irregular retro-areolar masses on mammography.¹¹⁴ Mammograms in diagnosing MBC were reported to have 92% to 100% sensitivity and 90% to 96% of specificity.¹⁹

Additionally, various breast biopsy methods such as fine needle aspiration (FNA) to differentiate malignant from non-malignant type of breast disease in men,¹¹⁵ core needle biopsy (CNB), surgical biopsy, and lymph node biopsy can also be employed. However, identification of specific markers those associated with MBC via., molecular profiling could pave way to discover and/or identify newer therapeutic strategies. Chatterji et al have systematically reviewed the existing prognostic MBC marker data for a period of 29 years and reported that consolidated all existing prognostic biomarker data in MBC spanning genetics, transcriptomics, proteomics, and epigenetics, and phenotypic features of prognostic value from articles published over a 29-year period (March 16, 1992, to May 1, 2021).¹¹⁶ Additionally, they also reported 4 epigenetics-based clusters from the relative promoter hypermethylation levels of RASSF1A, GSTP1, WIF1, RARB, and MAL. Notably, cluster 3 associated with mutated BRCA2. The authors have also reported that a subgroup analysis on BRCA2-mutated MBCs can be separated into 2 clusters based on the hypermethylation levels of GSTP1, MAL, and RASSF1A.¹¹⁶

A new horizon in understanding of cancer biology has been attained with the multi-omics molecular characterization of cancer. Despite, a major confounding factor that hampers a vigorous and reproducible tool involving bioinformatic analysis is that the diverse types of cells which are not only limited to the cancerous cells but also to the tumor microenvironmental cells those are adjacent to the normal cells could also present in biopsy of any tumor.¹¹⁷

Turajlic et al have reported that a snapshot of the genetic landscape of most of the cancer types could be determined using the next-generation sequencing with an insight of the cancer genomics approach which could emerge newer evolutionary patterns.¹¹⁸ The authors have also stated that an evolutionary framework could be a powerful tool to understand not only the cancer progression and/or the treatment failure but also could be a predictive tool to assess the tumor behavior and strategize treatment support.¹¹⁸ Similarly, Siavoshi et al have also reported that analysis of multiple gene differential expression profile datasets by using Gene Ontology (GO) and Kyot Encyclopedia of Genes and Genomes (KEGG) for protein–protein interaction (PPI) network analysis could be used to define the hub genes.¹¹⁹ Furthermore, the authors have also stated that Gene Expression Profiling Interactive Analysis (GEPIA) could be used to determine the relative mRNA expression of the hub gene, and thereby a prognostic gene signature can be identified.¹¹⁹

Hence, in the current review we have sought the PPIs of 20 different proteins that play major role in MBC which has been sorted out based on the STRING mapping (Figure 3).

Figure 3.

Protein–protein interaction of all 20 proteins in MBC using STRING.

It is clearly evident that BRCA2, BRCA1, and PALB2 form a complex involved in exchanging DNA strands during DNA repair. CHEK2 and PTEN collaborate in suppressing tumor growth through their regulation of the PI3K-Akt signaling pathway. TP53 and RAD51C work together in DNA repair and apoptosis. RAD51D, NBN, and ATM are all involved in the homologous recombination process of DNA repair. STK11 and CDH1 regulate the Hippo signaling pathway and regulate cell growth and apoptosis. MRE11A, MLH1, MSH2, and MSH6 form the MutL complex and control DNA mismatch repair. PPM1D and RAD51 form a complex and function in the DNA damage response. RAD50 and BARD1 work together in DNA repair by coordinating single-stranded breaks.

Treatment Modalities

Owing limited information available regarding the treatment options for men diagnosed with MBC, currently the treatment strategies for MBC are mostly based on the FBC guidelines.^117,120 Even though the disease characteristics are similar to FBC, with the understanding of the distinct clinical features, treatment strategies for MBC require a specific clinical approach.¹²¹ Therefore, in the recent years involving men in BC clinical trials are growing. Several studies have reported that OS of MBC is comparatively lower than FBC.^122‐124 In contrast to the above studies, it is also reported that on comparison with women, men have a slightly better or equivalent disease-specific survival.^125,126

Various modalities those are currently being practiced for the treatment of MBC have been shown in Figure 4.

Figure 4.

Treatment modalities for the MBC patients.

Based on search of literature, the treatment for early stage or non-metastatic MBCs includes the following^127‐130:

Surgery

Radiation therapy

Chemotherapy

Hormonal therapy

Earlier, Scott-Conner¹⁰⁶ and his colleagues have also reported that men with BC would also be treated with:

Modified radical mastectomy

Axillary lymph node dissection

Sentinel node biopsy

Beside which, the other options may include breast conservation or nipple-sparing of skin-sparing mastectomies. With respect to the limited number of studies and data for the use of chemotherapy to treat MBC, clinicians would prefer to assess the typical factors that has similar features of the FBC with early-stage of the disease.¹²¹ With large tumors or nodal involvement and if BCS is anticipated, neoadjuvant therapy could be employed to reduce the tumor size for the feasibility of BCS.¹³¹

Modified radical mastectomy is one of the most chosen surgical treatment for MBCs despite of radical mastectomy, where some of the less favored approaches including total mastectomy, and lumpectomy with or without radiation especially in patients of older age.¹³² Recently, a large population-cohort study evaluated the data of 16,498 MBCs from the National Cancer Database and has reported that treatments involving surgical methods showed an improved rate of survival.¹³³ Oppositely, Yadav et al have reported a negative association with mastectomy.¹³⁴ However, both the studies have also reported that increase in age, black ethnicity, government insurance, accumulated comorbidities and later stage with high grade tumors were highly associated with worse prognosis and decreased survival.^133,134 Despite, Yadav et al have reported that comparatively more male patients have underwent total mastectomy rather breast-conserving treatment, which is the most preferred option for female patients undergoing surgical treatment.¹³⁴ Moreover, 2 different studies from a European and USA Center have stated that sentinel lymph node biopsy is a reliable tool for the identification of nodal metastases.^135,136 Considering that there is no strong evidence available for the use of radiation after mastectomy, adhering the guidelines for FBC is the current recommendations as shown in few of the single institutional experiences.^137,138

Owing that hormonal therapy (HT) is considered to be the gold standard treatment option for hormone receptor positive in MBC, tamoxifen is characterized as adjuvant HT for 5 years which is associated to reduced risk of recurrence, representing by 51% in comparison to the treatment of FBC.¹³⁹ Aromatase pathway is responsible for about 80% of the total estrogen produced in male and 20% of which is produced by the testes.¹⁴⁰ Inhibiting the aromatase pathway that is responsible for the major production of estrogen could be one of the right choices of MBC treatment. However, studies focusing the role of adjuvant AIs in male patients is very limited.¹⁴¹ A study by Eggermann et al has compared the adjuvant tamoxifen versus AIs and reported that the outcome in AI cohort was statistically not significant for both mortality risk and OS.¹⁴² In general adjuvant chemotherapy could also be recommended on considering the age, high tumor grade, and/or the involvement of axillary nodes. However, it is also reported that adjuvant chemotherapy showed a statistically not significant results while considering lower time to recurrence and improvement of OS.¹³⁹ Based on literature search and the best of our knowledge, there is no data available related to the adjuvant use of trastuzumab in MBC treatment expect one case report with the speculation of its efficacy in metastatic disease.¹⁴³ The authors have also anticipated there is no specific biological reason for showing different activity of trastuzumab in MBC than in FBC, the use of trastuzumab and pertuzumab might be considered for treating HER-2-positive MBC.¹⁴³

In view of the greater number of MBC patients have hormone receptor positive, endocrine therapy using tamoxifen could be considered as first-line of choice while choosing the treatment option for the MBC patients.¹⁴⁴ AI could be used in combination with gonadotropin releasing hormone where the disease is progressed even after with tamoxifen treatment.¹⁴⁵ Recent studies have also emphasized a partial response with the use of selective ER degrader fulvestrant for the treatment of MBC.^102,146,147 Agents targeting endocrine and other specific targets such as mTOR and CDK and its combinations are also suggested in treating MBC patients. The same chemotherapeutic agents and regimens that are being used to treat FBC could be used for metastatic MBC treatment.^{92,113,117,148}

Targeted Treatments: Precision Medicine in MBC

The advent of targeted therapies marks a significant stride in the field of oncology. Yang et al has reported that, Epirubicin (EPI), upon entering the BC cells under the guidance of the targeting NKA-α1 peptide, exhibited a gradual release from the nanocarrier.¹⁴⁹ The controlled delivery and subsequent release of EPI within the BC cells resulted in significant inhibition of cell proliferation and migration in vitro and led to a substantial reduction in tumor volume in vivo.¹⁴⁹ The introduction of lumpectomy as a treatment for BC marked a significant advancement in disease management. Onik in 2004 has suggested that a procedure akin to a “male lumpectomy”—one that precisely targets the cancerous portion of the prostate gland while minimizing patient morbidity—is indeed feasible.¹⁵⁰ The authors have also stated that at a time when patients are faced with the choice between “watchful waiting” or potentially high-morbidity whole-gland treatments, such a focal approach would be a highly welcomed addition to the treatment options available.¹⁵⁰ Overall, the well-being and quality of life of individual patients could be successfully integrated into the general approach to cancer treatment, all while maintaining treatment efficacy.

Immunotherapies: Unleashing the Immune System Against MBC

Immunotherapies have revolutionized cancer treatment by harnessing the body's immune system to recognize and eliminate malignant cells.¹⁵¹ This approach has yielded extraordinary outcomes across various malignancies, prompting exploration in the realm of MBC. Immune checkpoint inhibitors (ICPIs), a class of immunotherapeutic agents, have shown potential in enhancing immune response against cancer cells. Recent trials investigating the efficacy of ICPIs in MBC have demonstrated encouraging results, warranting further investigation into their role as a viable treatment option.^152,153 Combination therapies involving immunomodulatory agents, such as ICPIs with targeted treatments, have also emerged as a promising avenue. Studies have indicated synergistic effects, underscoring the potential of a multifaceted therapeutic approach in MBC.^154,155

Biomarker-Driven Patient Categorization: Paving the Way for Personalized Therapy

The identification of specific biomarkers holds paramount importance in tailoring treatment strategies for MBC. Biomarkers serve as critical indicators, guiding therapeutic decisions and enabling a more personalized approach to patient care. Genomic profiling has emerged as a powerful tool in characterizing the molecular landscape of MBC. Studies have identified distinct genomic alterations in MBC, highlighting potential targets for therapy.^156,157 Moreover, the integration of liquid biopsies for the detection of circulating tumor DNA (ctDNA) has shown promise in monitoring disease progression and identifying actionable mutations in MBC.^158,159 This non-invasive approach offers a valuable avenue for real-time monitoring and treatment adjustment.

One promising avenue in targeted therapy for MBC involves the inhibition of hormonal receptors. ER positive MBC, though less common in men than women, represents a significant subset. Recent studies have highlighted the effectiveness of anti-estrogen agents like tamoxifen and AIs in male patients, emphasizing the importance of tailored hormonal therapies.^160‐162 HER2-targeted therapies have shown remarkable success in HER2-positive BC cases. Although less prevalent in MBC, the presence of HER2 amplification necessitates targeted intervention. Studies exploring the efficacy of anti-HER2 agents like trastuzumab have demonstrated promising results in male patients, underlining the importance of targeted treatments in specific molecular contexts.^163,164

Understanding the unique challenges and experiences faced by men with BC can lead to more effective and tailored treatment strategies. Some of the few key points that could be considered in such analysis have been summarized in Table 3.

Table 3.

Comparison Table for the Disease Progression, Treatment Responses, and Quality of Life in Male and Female Breast Cancer.

Tailored treatment strategies	Male breast cancer	Female breast cancer
Disease progression	Explore specific risk factors and genetic predispositions that may contribute to BC in men.	Highlight differences in disease presentation, including tumor characteristics, histology, and prevalence of subtypes.
Disease progression	Investigate any gender-specific variations in tumor biology, hormone receptor status, and other molecular characteristics of MBC.	Consider hormonal influences and their impact on disease progression in female patients.
Treatment response	Evaluate the efficacy and tolerability of standard breast cancer treatments in male patients, including surgery, chemotherapy, radiation therapy, hormone therapy, and targeted therapies.	Emphasize established treatment approaches for female breast cancer and their effectiveness based on factors like hormone receptor status, HER2 status, and molecular subtypes.
Treatment response	Investigate any potential gender-specific differences in response rates, side effects, and long-term outcomes.	Address nuances in treatment responses related to hormonal influences and menopausal status.
Quality of life	Examine the psychosocial, emotional, and physical challenges faced by men with MBC, including issues related to body image, self-esteem, and masculinity.	Consider quality of life factors such as body image, fertility concerns, and menopausal symptoms that may be particularly relevant to female patients.
Quality of life	Explore the availability and effectiveness of support networks and resources specifically tailored for male breast cancer patients.	Evaluate the impact of support systems, survivorship programs, and psychological interventions on the well-being of female breast cancer survivors.

Future Directions

Men with BC have an increased risk of developing secondary malignancies, such as secondary primary BC, cutaneous melanoma, stomach cancer, leukemia, and prostate cancer. The use of AIs to treat MBC may contribute to the development of prostate cancer. Diagnosis of MBC involves a complete family history, physical examination, bilateral ultrasound evaluation for younger men, and mammography as well. Biopsy methods, including FNA, CNB, surgical biopsy, and lymph node biopsy, can help in diagnosing the disease. Screening guidelines for MBC are not well established, leading to late-stage diagnosis and poorer outcomes. Implementation of proper guidelines for MBC and early detection can improve treatment success.

Conclusion

In conclusion, MBC is a rare but increasingly diagnosed condition. The current study emphasizes the urgent need for increased awareness and understanding of BC in men. The identified risk factors, including genetic predisposition, environmental exposures, occupational hazards, and lifestyle factors, highlight the complex nature of MBC etiology has been comprehensively reviewed. Even though the diagnosis and treatment modalities for MBC encompass a range of options, the comparison shows that the guidelines for MBC largely rely on those developed for FBC. It is clear that even with the adjusted differences in patients’ clinical characteristics, the death rate in men is higher than in women across all stages of BC. Hence, there is a need for prospective studies specifically focused on MBC to provide more tailored approaches. Hence, there is an immediate need to develop different clinical methods with a multinational approach to further improve the care of MBC patients. Strategic studies aiming to identify novel biomarkers specific to MBC and advancements in targeted treatments hold the potential to improve outcomes and save lives. It is important to raise awareness, improve knowledge, and develop tailored strategies for the prevention, early detection, and treatment regimens for MBC.

Footnotes

Abbreviations

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Sivanesan Dhandayuthapani

References

World Health Organization. Global Health Observatory. Geneva: World Health Organization; 2018. Available: who. int/gho/database/en/

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424.

Sung

Ferlay

Siegel

, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.

Gomig

Gontarski

Cavalli

, et al. Integrated analysis of label-free quantitative proteomics and bioinformatics reveal insights into signaling pathways in male breast cancer. Genet Mol Biol. 2021;44(1):e20190410. https://doi.org/10.1590/1678-4685-GMB-2019-0410

Staruch

Rouhani

Ellabban

. The surgical management of male breast cancer: time for an easy access national reporting database? Ann Med Surg. 2016;9:41‐49. https://doi.org/10.1016/j.amsu.2016.06.001

Maguire

Tomczyk

Perrakis

, et al. Rare variants in DNA damage repair genes are associated with male breast cancer predisposition. Cancer Res. 2018;78(13_Supplement):1225.

Giordano

Buzdar

Hortobagyi

. Breast cancer in men. Ann Intern Med. 2002, 15;137(8):678‐687.

Cui

. The prevalence and death risk of male breast cancer: a study based on the surveillance, epidemiology, and end results database. Am J Mens Health. 2022;16(1):15579883221074818.

Hodgson

Button

Franceschi

Moffat

Livingstone

. Male breast cancer: Is the incidence increasing? Ann Surg Oncol. 2004;11(8):751‐755. https://doi.org/10.1245/ASO.2004.01.001

10.

Sundriyal

Kotwal

Dawar

Parthasarathy

. Male breast cancer in India: series from a cancer research centre. Indian J Surg Oncol. 2015;6(4):384‐386.

11.

Chantra

Shiroshi

Wollman

Bassett

. In: Bassett

Jackson

, eds. Diagnosis of diseases of the breast, 2nd ed. Saunders; 2005:531‐556.

12.

Chen

Chantra

Larsen

, et al. Imaging characteristics of malignant lesions of the male breast. Radiographics. 2006;26(4):993‐1006.

13.

Shen

Liu

, et al. Analysis of genotype and age distribution of cervical human papillomavirus infection in Futian District, Shenzhen. China Eur J Gynaecol Oncol. 2023;44(3):83‐88.

14.

Campos

FAB

Rouleau

Torrezan

, et al. Genetic landscape of male breast cancer. Cancers. 2021;13(14):3535. https://doi.org/10.3390/cancers13143535

15.

Lee

Moon

Kim

. BRCA1/BRCA2 Pathogenic variant breast cancer: Treatment and prevention strategies. Ann Lab Med. 2020;40(2):114.

16.

Hussain

Selaibeekh

Almozher

, et al. Overview on epidemiology, causes and management of gynecomastia. Saudi Med Horiz J. 2024;4(1):19‐24.

17.

Expert Panel on Breast Imaging, Niell

Lourenco

Moy

, et al. ACR Appropriateness criteria® evaluation of the symptomatic male breast. J Am Coll Radiol 2018;15(11S):S313‐S320. https://doi.org/10.1016/j.jacr.2018.09.017

18.

Muñoz Carrasco

Alvarez Benito

Muñoz Gomariz

Raya Povedano

Martínez Paredes

. Mammography and ultrasound in the evaluation of male breast disease. Eur Radiol. 2010;20(12):2797‐2805. https://doi.org/10.1007/s00330-010-1867-7

19.

Woods

Salkowski

Elezaby

Burnside

Strigel

Fowler

. Image-based screening for men at high risk for breast cancer: benefits and drawbacks. Clin Imaging. 2020;60(1):84‐89.

20.

Liu

Johnson

. Male breast cancer: An updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer. 2018;18(5):e997‐1002.

21.

Tajima

Tsukuma

Oshima

. Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol. 2001;11(1):1‐7.

22.

Roy

Biswas

Datta

. Breast cancer: epidemiology, types, diagnosis, and treatment. In: Genetics and epigenetics of breast cancer. Vol 11. Singapore: Springer Nature Singapore, 2023, pp. 1‐24. https://doi.org/10.1007/978-981-19-9925-3

23.

Howlader

Noone

Krapcho

, et al. SEER Cancer statistics review, 1975–2018. National Cancer Institute. 2021;15:1‐25.

24.

Society

A.C.

Cancer A-Z. Available online: https://www.cancer.org/cancer/breast-cancer.html (Accessed on July 7th, 2023).

25.

Chen

Shi

, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017. Breast Cancer Res Treat. 2020;180(2):481‐490.

26.

Zeinomar

Bandera

Qin

. Toward understanding the etiology of male breast cancer: an ongoing research challenge. JNCI Cancer Spectrum. 2021;5(5):pkab079.

27.

Ishii

Nakano

Watanabe

Higashi

. Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan. Cancer Med. 2020;9(16):6069‐6075.

28.

Stitt

Vujovic

, et al. Male breast cancer prognostic factors versus female counterparts with propensity scores and matched-pair analysis. Cureus. 2015, 16;7(10):e355. https://doi.org/10.7759/cureus.355

29.

Valentini

Silvestri

Bucalo

, et al. Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology. Front Oncol. 2023;12:1092201. https://doi.org/10.3389/fonc.2022.1092201

30.

Chhabra

Chintamani Kadyaprath

, et al. Male breast cancer—an Indian multicenter series of 106 cases. Indian J Surg. 2021;83(S2):333‐340.

31.

Khandelwal

Goel

Sharma

, et al. Presentation and spectrum of male breast cancer in a rural cancer center in a subunit of Tata Memorial Center, India. Indian J Surg Oncol. 2021;12(2):330‐334.

32.

Korde

Zujewski

Kamin

, et al. Multidisciplinary meeting on male breast cancer: Summary and research recommendations. J Clin Oncol. 2010;28(12):2114.

33.

Cardoso

Bartlett

Slaets

, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405‐417.

34.

Boffano

Agnone

Zanellato

Brucoli

Rocchetti

. Breast ductal infiltrative adenocarcinoma metastasis to the mandible. J Maxillofac Oral Surg. 2023;22(4):1176‐1179.

35.

Fentiman

. Risk factors for male breast cancer. Am J Transl Res. 2023;15(12):6918.

36.

Ojara

. Carcinoma of the male breast in Mulago Hospital, Kampala. East Afr Med J. 1978;55(10):489‐491.

37.

Gnerlich

Deshpande

Jeffe

Seelam

Kimbuende

Margenthaler

. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837‐1844. https://doi.org/10.1245/s10434-010-1468-3

38.

De Los Santos

. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Breast Dis. 2012;2(23):138‐140.

39.

Constantinou

Marshall

. Discussion and optimization of the male breast cancer patient experience. J Breast Imag. 2023;5(3):339‐345.

40.

Macciotta

Catalano

Giraudo

, et al. Mediating role of lifestyle behaviors in the association between education and cancer: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2023;32(1):132‐140.

41.

Montagnese

Porciello

Vitale

, et al. Quality of life in women diagnosed with breast cancer after a 12-month treatment of lifestyle modifications. Nutrients. 2020;13(1):136.

42.

Coughlin

SS.

Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019;177(3):537‐548. https://doi.org/10.1007/s10549-019-05340-7

43.

Hsing

McLaughlin

Cocco

Co Chien

Fraumeni

. Risk factors for male breast cancer (United States). Cancer Causes Control. 1998;9(3):269‐275.

44.

Davies

Batehup

Thomas

. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105(1):S52‐S73.

45.

Rinninella

Mele

Cintoni

, et al. The facts about food after cancer diagnosis: a systematic review of prospective cohort studies. Nutrients. 2020;12(8):2345.

46.

Debras

Chazelas

Srour

, et al. Total and added sugar intakes, sugar types, and cancer risk: results from the prospective NutriNet-Santé cohort. Am J Clin Nutr. 2020;112(5):1267‐1279.

47.

Zakhari

Hoek

. Epidemiology of moderate alcohol consumption and breast cancer: association or causation? Cancers. 2018;10(10):349.

48.

, et al. Dietary patterns and breast cancer risk, prognosis, and quality of life: a systematic review. Front Nutr. 2023;9:1057057. https://doi.org/10.3389/fnut.2022.1057057

49.

Astori

Garavaglia

Colombo

, et al. Antioxidants in smokers. Nutr Res Rev. 2022;35(1):70‐97.

50.

Gray

. Cancer-Free with food: A step-by-step plan with 100+ recipes to fight disease, nourish your body & restore your health. Hay House, Inc; 2019.

51.

Ikram

Saeed

Afzaal

, et al. Nutritional and end-use perspectives of sprouted grains: a comprehensive review. Food Sci Nutr. 2021;9(8):4617‐4628.

52.

Wang

Bhupathiraju

, et al. Fruit and vegetable intake and mortality: results from 2 prospective cohort studies of US men and women and a meta-analysis of 26 cohort studies. Circulation. 2021;143(17):1642‐1654.

53.

Hughes

Pearson

Grafenauer

. Legumes-a comprehensive exploration of global food-based dietary guidelines and consumption. Nutrients. 2022;14(15):3080.

54.

Adams

. The complete guide to the keto diet: Lose weight, improve health, and boost energy. BoD–Books on Demand; 2023.

55.

Alagawany

Elnesr

Farag

, et al. Nutritional significance and health benefits of omega-3,-6 and-9 fatty acids in animals. Anim Biotechnol. 2022;33(7):1678‐1690.

56.

Chakraborty

. Antioxidants and ageing. In: Evidence-based functional foods for prevention of age-related diseases. Springer Nature Singapore; 2023, 61‐80.

57.

Kanlaya

Thongboonkerd

. Protective effects of epigallocatechin-3-gallate from green tea in various kidney diseases. Adv Nutr. 2019 Jan 1;10(1):112‐121.

58.

Kępińska-Pacelik

Biel

. Turmeric and curcumin—health-promoting properties in humans versus dogs. Int J Mol Sci. 2023 Sep 26;24(19):14561.

59.

Fabian

Kimler

Hursting

. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res. 2015;17(1):1‐1.

60.

Luo

Chen

, et al. Increased lipogenesis is critical for self-renewal and growth of breast cancer stem cells: impact of omega-3 fatty acids. Stem Cells. 2021 Dec 1;39(12):1660‐1670.

61.

Martínez

Herrera

Frías

, et al. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. Clin Transl Oncol. 2019;21(4):489‐498. https://doi.org/10.1007/s12094-018-1950-0

62.

Calado

Neves

Santos

Ravasco

. The effect of flaxseed in breast cancer: a literature review. Front Nutr. 2018;5:4. https://doi.org/10.3389/fnut.2018.00004

63.

Pritzlaff

Summerour

McFarland

, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat. 2017;161(3):575‐586. https://doi.org/10.1007/s10549-016-4085-4

64.

Fostira

Saloustros

Apostolou

, et al. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Res Treat. 2018;169(1):105‐113. https://doi.org/10.1007/s10549-018-4661-x

65.

Bucalo

Conti

Valentini

, et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study. Eur J Cancer. 2023;188:183‐191. https://doi.org/10.1016/j.ejca.2023.04.022

66.

Huang

Shen

Wang

, et al. LOH12CR1 Is a novel tumor suppressor inhibiting tumor growth through deregulation of G1/S checkpoint in human colorectal carcinoma. Curr Mol Med. 2018 Jan 1;18(1):25‐35.

67.

Talwar

Jain

. The genetic basis of breast cancer: a comprehensive overview. Curr Med Res Prac. 2023 May 1;13(3):97.

68.

Kaur

Kumar

Shafi

Vashistha

Kulharia

Munshi

. A study of mechanistic mapping of novel SNPs to male breast cancer. Med Oncol. 2019;36(8):70. https://doi.org/10.1007/s12032-019-1290-0

69.

Bell

Barraclough

Vasieva

. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med. 2017 Mar 1;17(3):200‐210.

70.

Watanabe

Miura

Kurata

Kitazawa

Kikugawa

Saika

. Spatial gene expression analysis reveals characteristic gene expression patterns of De Novo neuroendocrine prostate cancer coexisting with androgen receptor pathway prostate cancer. Int J Mol Sci. 2023 May 18;24(10):8955.

71.

Tan

Marchio

Reis-Filho

. Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol. 2008 Oct 1;61(10):1073‐1082.

72.

German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002 Feb 1;97(4):472‐480.

73.

Thompson

Doyle

Ryland

, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 2012;8(9):e1002894. https://doi.org/10.1371/journal.pgen.1002894

74.

Cybulski

Gorski

Huzarski

, et al. CHEK2 Is a multiorgan cancer susceptibility gene. Am J Hum Gene. 2004 Dec 1;75(6):1131‐1135.

75.

Corridoni

Chapman

Ambrose

Simmons

. Emerging mechanisms of innate immunity and their translational potential in inflammatory bowel disease. Front Med. 2018;5:32. https://doi.org/10.3389/fmed.2018.00032

76.

Evans

Woodward

Bajalica-Lagercrantz

Oliveira

Frebourg

. Germline TP53 testing in breast cancers: why, when and how? Cancers. 2020 Dec 14;12(12):3762.

77.

Bouaoun

Sonkin

Ardin

, et al. TP53 Variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016 Sep;37(9):865‐876.

78.

Sopik

Narod

. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170(3):647‐656. https://doi.org/10.1007/s10549-018-4796-9

79.

Golmard

Caux-Moncoutier

Davy

, et al. Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer. 2013;13:484. https://doi.org/10.1186/1471-2407-13-484

80.

Renwick

Thompson

Seal

, et al. ATM Mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006 Aug 1;38(8):873‐875.

81.

Iacobuzio-Donahue

. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012 Jul 1;61(7):1085‐1094.

82.

Brooks-Wilson

Kaurah

Suriano

, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004 Jul 1;41(7):508‐517.

83.

Bian

Meng

Zhang

. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol Cancer. 2019 Dec;18(1):1‐4.

84.

Jass

. Diagnosis of hereditary non-polyposis colorectal cancer. Histopathology. 1998 Jun;32(6):491‐497.

85.

Bärlund

Kuukasjärvi

Syrjäkoski

Auvinen

Kallioniemi

Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004 Oct 10;111(6):968‐971.

86.

Malone

Begg

Haile

, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010 May 5;28(14):2404.

87.

Vijai

Kirchhoff

Schrader

, et al. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet. 2013 Jan 17;9(1):e1003220.

88.

Shah

Robbani

Shah

. Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med. 2009 Jul;29(4):288‐293.

89.

Aryannejad

Saeedi Moghaddam

Mashinchi

, et al. National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019. Breast Cancer Res. 2023 Dec;25(1):1‐26.

90.

Nikolić

Mićanović

Mitrašinović

Murtezani

Banašević

Šipetić-Grujičić

. Incidence and mortality from breast cancer in the male and female population of Central Serbia in the period 2009–2020. Zdravstvena Zaštita. 2023;52(1):8‐25.

91.

du Plessis

Fourie

Stone

Engelbrecht

. The impact of endocrine disrupting compounds and carcinogens in wastewater: implications for breast cancer. Biochimie. 2023;209:103-115. https://doi.org/10.1016/j.biochi.2023.02.006

92.

Daniels

Aduse-Poku

Gawu

. Overview of male breast cancer. World J Adv Res Rev. 2023;17(2):010‐022.

93.

Alagan

Kishore

Perumal

, et al. Narrative of hazardous chemicals in water: its potential removal approach and health effects. Chemosphere. 2023;335:139178. https://doi.org/10.1016/j.chemosphere.2023.139178

94.

Nicosia

Lissidini

Sargenti

, et al. Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center. Breast Cancer Res Treat. 2022 Nov;196(2):371‐377.

95.

Sakhri

Jaidane

Bouhani

, et al. Pure ductal carcinoma in situ in the male breast: a rare entity. Eur J Breast Health. 2020;16(1):77‐80.

96.

Ionescu

Madge

Dicu-Andreescu

, et al. Breast cancer in male patients: correlation between immunohistochemistry and diagnosis and treatment challenges. Eur J Surg Oncol. 2023 Feb 1;49(2):e80.

97.

Singh

Kumar Sain

. Etiology of breast cancer. J Pharm Negat Results. 2023;14(3):1427‐1434. https://doi.org/10.47750/pnr.2023.14.03.192

98.

Elbasyouni

Soro

Nshimirimana

. Understanding breast cancer: a key emphasis on molecular signalling pathways and phytotherapy. Int J Oncol Radio. 2023;4(2):1‐5.

99.

Gogia

Raina

Deo

Shukla

Mohanti

. Male breast cancer: a single institute experience. Indian J Cancer. 2015 Oct 1;52(4):526‐529.

100.

Shandiz

Tavassoli

Sharifi

Khales

Kadkhodayan

Khales

. Hormone receptor expression and clinicopathologic features in male and female breast cancer. Asian Pac J Cancer Prev. 2015;16(2):471‐474.

101.

Law

Piotrowski

Ning

Jiang

Ding

Sahin

. Trichorhinophalangeal Syndrome Type 1 (TRPS1) expression in male breast carcinoma. Hum Pathol. 2023;138:62-67. https://doi.org/10.1016/j.humpath.2023.06.005

102.

Bhatia

Hazra

Thareja

. Selective estrogen receptor degraders (SERDs) for the treatment of breast cancer: an overview. Eur J Med Chem. 2023;256:115422. https://doi.org/10.1016/j.ejmech.2023.115422

103.

Nahleh

Srikantiah

Safa

Jazieh

Muhleman

Komrokji

. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007 Apr 15;109(8):1471‐1477.

104.

Yalaza

İnan

Bozer

. Male breast cancer. J Breast Health. 2016 Jan;12(1):1.

105.

Goss

Reid

Pintilie

Lim

Miller

. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999 Feb 1;85(3):629‐639.

106.

Scott-Conner

Jochimsen

Menck

Winchester

. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999 Oct 1;126(4):775‐781.

107.

Satram-Hoang

Ziogas

Anton-Culver

. Risk of second primary cancer in men with breast cancer. Breast Cancer Res. 2007 Feb;9(1):1‐7.

108.

Lee

Jones

. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis. 2009 Mar;12(1):52‐56.

109.

Zengin

Şahin

Çiftçi

Alternative pharmacological approach to male infertility: anti-aromatase compounds: a systematic review. J Reconst Urol. 2023 Jan 1;13(1):28-37. https://doi.org/10.5336/urology.2022-92478

110.

Grenader

Goldberg

Shavit

. Second cancers in patients with male breast cancer: a literature review. J Cancer Surviv. 2008;2(2):73‐78. https://doi.org/10.1007/s11764-008-0042-5

111.

Lee

Kwong

. Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer. Cancer Med. 2020 May;9(10):3305‐3309.

112.

Xia

Zhou

Guo

, et al. Chinese Female breast cancer patients show a better overall survival than their male counterparts. Chin Med J. 2010 Sep 5;123(17):2347‐2352.

113.

Niell

Lourenco

Moy

, et al. ACR appropriateness Criteria® evaluation of the symptomatic male breast. J Am Coll Radiol. 2018 Nov 1;15(11):S313‐S320.

114.

Yen

Sinha

Barnes

Butt

Iles

. Benign and malignant male breast diseases: radiologic and pathologic correlation. Can Assoc Radiol J. 2015 Aug;66(3):198‐207.

115.

Chretien

Aymes

Barthoulot

, et al. 181P Male breast cancer (MBC): familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts). ESMO Open. 2023 May 1;8(1):101458. https://doi.org/10.1016/j.esmoop.2023.101458

116.

Chatterji

Krzoska

Thoroughgood

, et al. Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review. Lancet Oncol. 2023 Feb 1;24(2):e74‐e85.

117.

Soni

Paul

Verma

Kaur

Chauhan

Kaushal

. Male breast cancer: a budding and unaddressed issue. Oncol Clin Prac. 2023;19(3):158-166. https://doi.org/10.5603/OCP.2023.0008

118.

Turajlic

Sottoriva

Graham

Swanton

. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019 Jul;20(7):404‐416.

119.

Siavoshi

Taghizadeh

Dookhe

Piran

. Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data. Genomics. 2022 Jan 1;114(1):161‐170.

120.

Niccolai

Baldi

Nannini

, et al. Breast cancer: the first comparative evaluation of oncobiome composition between males and females. Biol Sex Differ. 2023 Dec;14(1):1‐9.

121.

Gucalp

Traina

Eisner

, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173(1):37‐48. https://doi.org/10.1007/s10549-018-4921-9

122.

Yao

Shi

Liu

, et al. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Sci Rep. 2022 Jan 7;12(1):220.

123.

Wang

Liu

Xue

. Clinicopathological features and prognosis of male breast cancer. J Int Med Res. 2021 Oct;49(10):03000605211049977.

124.

Dogan

Aydin

, et al. Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: a single tertiary center experience. J Cancer Res Ther. 2023;9(7):1887-1892. https://doi.org/10.4103/jcrt.jcrt_243_22

125.

Clout

Murray

Farrell

Hutt

Kenyon

. Cell therapy, nursing implications and care. In: the European blood and marrow transplantation textbook for nurses: under the auspices of EBMT 2023 Apr 8. Springer International Publishing, 101‐122.

126.

Sidiropoulou

Vasconcelos

Couceiro

, et al. Prevalence of imaging detected silent male breast cancer in autopsy specimens: study of the disease held by image-guided biopsies. Acad Forensic Pathol. 2023 Mar;13(1):16‐33.

127.

Taji

Odan

Kataoka

, et al. Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study. Breast Cancer. 2023 Mar;30(2):309‐314.

128.

Masood

Nadeem

Masood

Ali

Tufail

. Association of paclitaxel induced neuropathy with quality of life of patients with non-metastatic breast cancer. Pak Armed Forces Med J. 2023 Jun 16;73(3):755‐758.

129.

Brosseau

Peláez

Ananng

Körner

Obstacles and facilitators of cancer-related dyadic efficacy experienced by couples coping with non-metastatic cancers. Front Psychol. 2023;14:949443. https://doi.org/10.3389/fpsyg.2023.949443

130.

Upadhyay

Prakash

Upadhyay

. Clinicopathological profile of breast cancer at a tertiary cancer center in Jharkhand, India: a descriptive cohort study. Cureus. 2023 Jun 5;15(6):e39990. https://doi.org/10.7759/cureus.39990

131.

Boughey

Bedrosian

Meric-Bernstam

, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct 1;203(4):475‐480.

132.

Cutuli

. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007;8(2):193‐202.

133.

Sarmiento

McColl

Musavi

, et al. Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database. Breast Cancer Res Treat. 2020;180(2):471‐479. https://doi.org/10.1007/s10549-020-05556-y

134.

Yadav

Karam

Bin Riaz

, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126(1):26‐36.

135.

Wernberg

Yap

Murekeyisoni

Mashtare

Wilding

Kulkarni

. Multiple primary tumors in men with breast cancer diagnoses: a SEER database review. J Surg Oncol. 2009;99(1):16‐19.

136.

Gentilini

Chagas

Zurrida

, et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist. 2007;12(5):512‐515.

137.

Korde

Zujewski

Kamin

, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114‐2122.

138.

Flynn

Park

Patil

Cody

3rd Port

. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg. 2008;206(4):616‐621.

139.

Suzuki

Younus

, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients—A case series. Int J Radiat Oncol Biol Phys. 2012;82(2):696‐700. https://doi.org/10.1016/j.ijrobp.2011.01.010

140.

Giordano

Perkins

Broglio

, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104(11):2359‐2364. https://doi.org/10.1002/cncr.21526

141.

Volm

. Male breast cancer. Curr Treat Options Oncol. 2003;4:159‐164. https://doi.org/10.1007/s11864-003-0017-8

142.

Eggemann

Ignatov

Smith

, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465‐470. https://doi.org/10.1007/s10549-012-2355-3

143.

Eggemann

Altmann

Costa

Ignatov

. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018;144(2):337‐341. https://doi.org/10.1007/s00432-017-2539-7

144.

Jacquet

Lardy-Cléaud

Pistilli

, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018;95:93‐101.

145.

Khan

Rojas

Schlumbrecht

Jeudin

. Oophorectomy in premenopausal patients with estrogen receptor-positive breast cancer: new insights into long-term effects. Curr Oncol. 2023 Feb 2;30(2):1794‐1804.

146.

Hanna

Moniz

Chan

, et al. Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer. Drugs Future. 2023 Jan 1;48(1).

147.

Gombos

Goncalves

Curigliano

, et al. How I treat endocrine-dependent metastatic breast cancer. ESMO Open. 2023 Apr 1;8(2):100882.

148.

Zheng

Leone

. Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. J Oncol. 2022;2022(1):1734049.

149.

Yang

Feng

Ding

, et al. Controllable drug delivery by Na+/K+ ATPase alpha1 targeting peptide conjugated DSPE-PEG nanocarriers for breast cancer. Technol Cancer Res Treat. 2021;20:15330338211027898. https://doi.org/10.1177/15330338211027898

150.

Onik

. The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat. 2004;3(4):365‐370.

151.

Sahu

Suryawanshi

. Immunotherapy: the future of cancer treatment. J Oral Maxillofac Pathol. 2021 May 1;25(2):371.

152.

Kossai

Radosevic-Robin

Penault-Llorca

. Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open. 2021;6(5):100257.

153.

Giordano

. Breast cancer in men. N Engl J Med. 2018;378(24):2311‐2320.

154.

Yap

Bardia

Dvorkin

, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol. 2023;9(1):40‐50.

155.

Freeman-Cook

Hoffman

Miller

, et al. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell. 2021;39(10):1404‐1421 e1411.

156.

Zerdan

Kumar

Haroun

Srivastava

Ross

Sivapiragasam

. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss. Oncotarget. 2023;14:178. https://doi.org/10.18632/oncotarget.28376

157.

Malone

Oliva

Sabatini

Stockley

Siu

. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(8):1‐9. https://doi.org/10.1186/s13073-019-0703-1

158.

Ranghiero

Frascarelli

Cursano

, et al. Circulating tumour DNA testing in metastatic breast cancer: integration with tissue testing. Cytopathology. 2023 Nov;34(6):519‐529.

159.

Keup

Kimmig

Kasimir-Bauer

. The diversity of liquid biopsies and their potential in breast cancer management. Cancers. 2023 Nov 17;15(22):5463.

160.

Rachner

Coleman

Hadji

Hofbauer

. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901‐910.

161.

Khan

NAJ

Tirona

. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. 2021;38(4):39.

162.

Vrselja

Latifi

Baber

, et al. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2022;400(10364):1704‐1711.

163.

Hurvitz

Hegg

Chung

, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105‐117.

164.

Cameron

Piccart-Gebhart

Gelber

, et al. T. Herceptin Adjuvant Trial Study. 11 Years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195‐1205.

Male Breast Cancer: Current Scenario and Future Perspectives

Abstract

Keywords

Introduction

Epidemiology

Etiology

Risk Factors

Role of Lifestyle Factors, Diet, and Exercise

Types

Ductal Carcinoma In Situ (DCIS)

Signs and Symptoms

Secondary Malignancies due to BC

Diagnosis

Treatment Modalities

Targeted Treatments: Precision Medicine in MBC

Immunotherapies: Unleashing the Immune System Against MBC

Biomarker-Driven Patient Categorization: Paving the Way for Personalized Therapy

Future Directions

Conclusion

Footnotes

Abbreviations

Declaration of Conflicting Interests

Funding

ORCID iD

References